Navigation Links
URMC clinical trial tests new regimen for hypertension
Date:4/26/2012

Researchers at the University of Rochester Medical Center are testing whether different doses of an established blood pressure medication can provide the same benefits as a standard dose in people with mild hypertension, possibly with fewer side effects and at a lower cost. The newly launched clinical trial, funded with a $1.9 million grant from the National Heart Lung and Blood Institute, is the first of its kind in the United States.

The study drug, carvedilol (brand name Coreg), is FDA approved and widely used for the treatment of high blood pressure. What researchers hope to learn is how varying amounts of the medication, including doses lower than typically prescribed, affect patients with mild or stage 1 hypertension a systolic pressure (top number) ranging from 140 to 160 mm Hg.

According to hypertension expert and study investigator John D. Bisognano, M.D., Ph.D., people with this early form of the disease are often advised to try lifestyle changes, such as eating a healthier diet and exercising, for six months to a year before initiating drug therapy. For individuals implementing lifestyle modifications who are also considering medical treatment, the trial provides an opportunity to try a safe and effective drug that, even at varying doses, may help bring their blood pressure back to healthy levels.

"It is so ingrained in everyone's mind that we have to have a constant level of medication, but it is possible that if the drug level goes down, the brain may be able to make up for that," said Bisognano, director of Cardiology Outpatient Services who will run the trial with Francisco A. Tausk, M.D., professor in the Departments of Dermatology and Psychiatry and Jan A. Moynihan, Ph.D., Engel Professor in Psychosocial Medicine also in the Department of Psychiatry at the Medical Center. "We may be able to meet the medical need with less medication in this low-risk population and potentially decrease side effects in the process."

Such an outcome would be a huge step forward for the millions of Americans with mild hypertension who are limited in the amount or number of medications that they can take because of adverse side effects. It may also appeal to the growing number of Americans who are skeptical of or want to avoid standard pharmaceuticals, a culture change that Bisognano and other physicians have witnessed in their practices over the past few years.

According to the Centers for Disease Control and Prevention, nearly a third of the nation's adults struggle with high blood pressure, which increases the risk of heart disease and stroke and represents a significant economic burden to society, with $54 billion spent on the condition in 2001 alone.

People with mild hypertension who pass a medical exam may be eligible for the study. Once enrolled, individuals will receive different daily amounts of the study drug for at least three and up to eight weeks. In addition to brief weekly visits, participants will be asked to: monitor their blood pressure every morning and evening; record their results and any side effects in a blood pressure diary; and fill out weekly questionnaires regarding how they feel and any noteworthy events or changes that took place.

Individuals who complete study weeks one through three will be paid $100, and those who go on to complete weeks four through eight will be paid another $100. All travel expenses for appointments will also be reimbursed.


'/>"/>
Contact: Emily Boynton
emily_boynton@urmc.rochester.edu
585-273-1757
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Stethoscope App gives iPhone New Clinical Skills
2. Sunquest Introduces Integrated Clinical Environment Physician Portal Solution in US
3. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
4. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
5. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
6. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
7. UCLA Health System Presents: How to Successfully Implement a Clinical Portal
8. TeraMedica Launches Evercore – Clinical Enterprise Suite 5.0 Now on Linux
9. Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options
10. MedQuist Launches EHR Integration for Dictations Associated with Template-based Clinical Documentation
11. Greenway Medical Technologies Donates Electronic Health Record, Clinical Research and Revenue Cycle Solutions to Northern Kentucky University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... On Saturday, ... a treadmill relay – Miles by Moonlight to raise money for the American Heart ... or more. , Teams will work together to keep their treadmills moving for ...
(Date:10/12/2017)... ... , ... In the United States, single-family home owners pay ... York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 a ... rates, which contributes to the relatively lower cost of living in places like ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance in ... medical-grade battery-powered display stand specifically designed for endoscopy environments. An innovative ... into a clinical solution to support the improvement of patient outcomes, ... Design ... Solution ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
Breaking Medicine Technology: